1stOncology™: Cancer Intelligence Service – Page 6347 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Abcuro Appoints H. Jeffrey Wilkins, M.D., as Chief Medical Officer

On June 21, 2022 Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, reported the appointment of H. Jeffrey Wilkins, M.D., as Chief Medical Officer (Press release, Abcuro, JUN 21, 2022, View Source [SID1234616124]). Dr. Wilkins brings deep experience in advancing clinical programs with a focus in immunology, rare diseases, and immuno-oncology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

"Jeff’s impressive track record and extensive experience in immunology, immuno-oncology, and rare disease clinical development make him an ideal fit for Abcuro at this pivotal time in our evolution," said John Edwards, Executive Chairman of Abcuro. "We are excited to welcome Jeff to our leadership team and look forward to working closely with him as we advance ABC008 into a late-stage clinical trial in inclusion body myositis (IBM) and initiate a clinical trial in T cell large granular lymphocytic leukemia (T-LGLL) this year."

"I am eager to bring my clinical development expertise to a talented Abcuro team at such an important time. I am impressed with ABC008’s ability to selectively deplete highly cytotoxic T cells, an immune cell population driving tissue damage in several autoimmune disorders, most prominently in IBM," said Dr. Wilkins. "I look forward to the opportunity to guide the clinical advancement of ABC008 across multiple indications and to progress ABC015 towards the clinic – both of which represent novel approaches to address important medical needs."

Dr. Wilkins brings more than twenty years of clinical research experience to Abcuro, most recently serving as Chief Medical Officer of Avalo Therapeutics, where he was responsible for clinical development for programs in immuno-oncology, immunology and orphan disease. Previously, he held the position of Chief Medical Officer at Lycera, and Ceptaris Therapeutics, where he led clinical programs from IND Phase I trials to regulatory approval (including Valchlor). Prior to this, Dr. Wilkins was Vice President, Worldwide Clinical Research, Inflammation/Oncology at Cephalon, Inc., where he was responsible for clinical development, medical affairs, and business development efforts in both therapeutic areas. He joined Cephalon via its acquisition of Ception Therapeutics, and as Senior Vice President of Clinical Development, headed a successful program in eosinophilic asthma. Dr. Wilkins entered the pharmaceutical industry with GlaxoSmithKline, where he rose to become Vice President of Discovery Medicine for GSK’s Center of Excellence in External Drug Discovery. Dr. Wilkins received his M.D. from Temple University School of Medicine and his B.S. from Bucknell University.

About ABC008
ABC008 is a first-in-class anti-KLRG1 antibody capable of selectively depleting highly cytotoxic T cells, while sparing regulatory and central memory T cells. ABC008 has been designed to treat diseases mediated by highly cytotoxic T cells, including the autoimmune muscle disease inclusion body myositis (IBM), T cell large granular lymphocytic leukemia (T-LGLL), and other mature T cell malignancies. The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to ABC008 for the treatment of IBM.

Ultima Genomics and Exact Sciences enter long-term supply agreement aimed at improving patient access to genomic testing by driving down sequencing costs

On June 21, 2022 Ultima Genomics, Inc. and Exact Sciences Corporation (Nasdaq: EXAS) reported that they have entered a long-term supply agreement for Ultima’s next-generation sequencing (NGS) technologies (Press release, Exact Sciences, JUN 21, 2022, View Source [SID1234616123]). Under the terms of the supply agreement, Ultima Genomics will provide access to its NGS products, which are based on a new architecture designed to enable sequencing at a fraction of the cost of other commercially available technologies . The companies also plan to develop one or more of Exact Sciences’ advanced cancer diagnostic tests using Ultima’s sequencing technology. In conjunction with the agreement, Exact Sciences became an investor in Ultima and joined its ongoing early access program for its high-throughput NGS instrument platform, the UG 100. The collaboration is aimed at driving down the high cost of sequencing to improve patient access to genomics-based testing and human health.

"Exact Sciences believes access to differentiated and affordable genomics technologies is critical to providing patients better information before diagnosis and across all stages of cancer treatment," said Kevin Conroy, chairman and CEO of Exact Sciences. "Ultima’s mission to drive down the cost of sequencing and increase the use of genomic information supports our goal to provide accurate and affordable testing options across the cancer continuum. This is particularly important for applications like cancer screening, minimal residual disease, and recurrence monitoring, which could lead to millions of tests per year."

"We founded Ultima Genomics with the mission to continuously drive the scale of genomic information. We believe our mission is closely aligned with the goals of our customers, and we look forward to enabling Exact Sciences and others to perform sequencing at a fraction of the cost today," said Gilad Almogy, CEO of Ultima Genomics. "We designed our new sequencing architecture to scale beyond conventional technologies, and are excited to soon make the UG 100, our first instrument using this architecture, commercially available to more customers. In the future, we aim to continuously improve our technology, further drive down costs, and increase the scale of genomic information to improve patient outcomes."

Over the last 5 years, Ultima Genomics has developed a fundamentally new sequencing architecture designed to scale beyond conventional approaches, including completely different flow cell engineering and sequencing chemistry, and machine learning. Ultima is currently in an early access program for the UG 100, its first high-throughput NGS instrument using this new technology architecture.

Kintara Therapeutics to Present at the Alliance Global Partners Summer Healthcare Conference

On June 21, 2022 Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, reported that President and CEO Robert E. Hoffman will present a corporate overview at the Alliance Global Partners Summer Healthcare Conference (Press release, Kintara Therapeutics, JUN 21, 2022, View Source [SID1234616122]). The conference is being held virtually on June 21 – 22, 2022.

Mr. Hoffman will be available for one-on-one meetings. For more information, please contact your registered AGP representative or [email protected].

Phynova and Ingredients Plus announce a distribution partnership to promote Reducose® in Oceania

On June 21, 2022 Phynova Group Ltd and Ingredients Plus reported a distribution partnership for Reducose, for use in Supplement applications to customers in Oceania (Press release, Phynova, JUN 21, 2022, View Source [SID1234616120]). Reducose is Phynova’s patented and clinically researched White Mulberry leaf extract that supports significant lowering of post-meal blood sugar and insulin response as well as enabling food and beverage applications to become Low GI.

Stephane Ducroux, CEO at Phynova, said: "We are delighted to have a distribution partnership with Ingredients Plus. Phynova’s strategy is to partner with market focused experts such as Ingredients Plus, who have a proven track record of building deep customer relationships and using ingredients with a strong science like Reducose.

Peter Schwarczer, Business Manager at Ingredients Plus said: "We are excited to partner with Phynova by bringing a unique ingredient into the ANZ market and we look forward to a long-term and fruitful cooperation."

Labcorp Enhances Clinical Trial and Drug Development Capabilities Through Real World Data Collaboration With HealthVerity

On June 21, 2022 Labcorp (NYSE: LH), a leading global life sciences company, reported a new collaboration with HealthVerity, Inc., the leader in Identity, Privacy, Governance, and Exchange (IPGE) for real-world data (RWD), that will expand Labcorp’s comprehensive, end-to-end drug development and clinical trial programs (Press release, LabCorp, JUN 21, 2022, View Source [SID1234616118]).

HealthVerity’s IPGE platform, an integrated technology and RWD infrastructure, enables Labcorp Drug Development and other participating companies to access fully interoperable, HIPAA-compliant data from the U.S.’s largest ecosystem1 of health care and consumer data.

"This collaboration allows Labcorp to expand existing end-to-end solutions for drug and diagnostics development, commercialization and clinical trial efforts to include large-scale access to real-world data for research applications," said Dr. Paul Kirchgraber, CEO of Labcorp Drug Development. "By applying advanced analytics, Labcorp can help its clients improve their processes and reach better outcomes. Our substantial repository of test results can also help study sponsors more quickly and accurately assess patient eligibility for clinical trials, enroll patients faster and accelerate the availability of new medicines."

Now more than ever, study sponsors are seeing the potential of RWD to yield longitudinal patient insights before, during and after trials. With more predictive analytics and artificial intelligence applications requiring comprehensive and fully interoperable RWD, Labcorp can align de-identified patient data with ten times greater accuracy2 than industry alternatives by using the HealthVerity IPGE platform. In addition, access to HealthVerity’s RWD with on-demand de-identification and data linkage capabilities reinforces Labcorp’s ability to be a trusted source of information for its clients.

"Fragmentation of patient data is at an all-time high, and the goal is no longer just connecting this data," said Andrew Kress, CEO of HealthVerity. "Rather, the goal is making data more accessible and useful for gaining a detailed understanding of patient journeys. With analytics and applications requiring more frictionless access to the data itself, the HealthVerity IPGE platform stands alone in offering the ability to combine transaction-level patient data in a de-identified, fully interoperable manner, and delivering it directly into the client’s applications of choice."

Labcorp is an investor in HealthVerity through the Labcorp Venture Fund.